Annals of Oncology

Print ISSN
0923-7534
Electronic ISSN
1569-8041
Impact factor
6.452
Publisher
highwire
URL
http://annonc.oxfordjournals.org
Usage rank
214
Article count
8874
Free count
5220
Free percentage
0.588235
PDFs via platforms
Proquest, Rcgp, Highwire from 1990, Rupress, Ama, Aacr, Csh, Ebscoatoz, CSA, Oxford University Press, Oxford, Ingenta, Aaas, Ebsconet, Endocrine, Nephrology, and Ovid from 2002

  1. Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer.

    Annals of Oncology 18 Suppl 10:x32 (2007) PMID 17761722

    Treatment outcomes for patients with metastatic non-small-cell lung cancer (NSCLC) are poor with chemotherapy. In recent years, novel agents that target specific, aberrant molecular pathways in NSCLC have been under evaluation in clinical trials. To date, just two targeted agents have impacted t...
  2. Advances in the treatment of gastrointestinal stromal tumours.

    Annals of Oncology 18 Suppl 10:x20 (2007) PMID 17761719

    Imatinib, a selective tyrosine kinase inhibitor, is currently the standard of care first-line treatment for unresectable or metastatic gastrointestinal stromal tumour (GIST), improving survival time and delaying disease progression in many patients. Nevertheless, primary and secondary (acquired)...
  3. Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Ann Oncol 2007; 18 Suppl 3: pp 1 75).

    Annals of Oncology 18(9):1433 (2007) PMID 17761703

  4. Questioning specialists' attitudes to breast cancer follow-up in primary care.

    Annals of Oncology 18(9):1467 (2007) PMID 17525086

    National Institute for Clinical Excellence (NICE) guidelines recommend discharging asymptomatic breast care patients 3 years after diagnosis. A role for General Practitioners (GPs) and breast care nurses is proposed, together with skills training, but it remains unclear for how long breast cance...
  5. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy.

    Annals of Oncology 18(9):1457 (2007) PMID 17351255

    Over the last two decades, several lines of experimental evidence have suggested that the gastrin-releasing peptide (GRP) may act as a growth factor in many types of cancer. For that reason, gastrin-releasing peptide receptor (GRPR) antagonists have been developed as anticancer candidate compoun...
  6. Timely disclosure of progress in childhood cancer survival by 'period' analysis in the Automated Childhood Cancer Information System.

    Annals of Oncology 18(9):1554 (2007) PMID 17698836

    A few years ago, a new method of survival analysis, denoted 'period' analysis, was introduced to provide more up-to-date survival estimates of cancer patients. We evaluated the period survival method using the large database of the Automated Childhood Cancer Information System (ACCIS). Our evalu...
  7. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.

    Annals of Oncology 18(9):1484 (2007) PMID 17761704

    Having demonstrated in a previous report that the response of circulating epithelial tumor cells (CETC) during the first cycles of primary (neoadjuvant) chemotherapy perfectly reflects the response of the tumor, in the present study the changes in cell numbers during subsequent cycles and their ...
  8. Prevalence of pain in patients with cancer: a systematic review of the past 40 years.

    Annals of Oncology 18(9):1437 (2007) PMID 17355955

    Despite the abundant literature on this topic, accurate prevalence estimates of pain in cancer patients are not available. We investigated the prevalence of pain in cancer patients according to the different disease stages and types of cancer. A systematic review of the literature was conducted....
  9. Up-to-date monitoring of childhood cancer long-term survival in Europe: methodology and application to all forms of cancer combined.

    Annals of Oncology 18(9):1561 (2007) PMID 17660498

    The Automated Childhood Cancer Information System (ACCIS) provides a unique database for monitoring and comparing long-term prognosis of children with cancer in Europe. The 'period' method has been shown particularly useful for that purpose. The ACCIS database was used for comparative analyses o...
  10. Breast cancer follow-up: just a burden, or much more?

    Annals of Oncology 18(9):1431 (2007) PMID 17761702

  11. Participation in screening colonoscopy in first-degree relatives from patients with colorectal cancer.

    Annals of Oncology 18(9):1518 (2007) PMID 17761708

    Current guidelines recommend screening colonoscopy in first-degree relatives of patients with colon cancer. The aim of this state-wide study was to investigate the compliance for colonoscopic in first-degree relatives, who were younger than 60 years of age. A total of 602 patients were identifie...
  12. Treatment options in renal cell carcinoma: past, present and future.

    Annals of Oncology 18 Suppl 10:x25 (2007) PMID 17761720

    Cytokine therapies have been the standard of care in metastatic renal cell carcinoma (RCC). However, these agents only provide clinical benefit to a small subset of patients and are associated with significant toxicity. A better understanding of the molecular biology of RCC has identified the va...
  13. Preferences regarding end-of-life cancer care and associations with good-death concepts: a population-based survey in Japan.

    Annals of Oncology 18(9):1539 (2007) PMID 17660496

    The aims of this study were to clarify end-of-life cancer care preferences and associations with good-death concepts. The general population was sampled using a stratified random sampling method (N = 2548; response rate = 51%) and bereaved families from 12 certified palliative care units ('PCU-b...
  14. Hematopoietic cell transplantation: progress and obstacles.

    Annals of Oncology 18(9):1450 (2007) PMID 17355954

    The use of hematopoietic cell transplantation has expanded and evolved substantially in the last decade. New stem cell sources and stem cell mobilizing agents have been introduced in clinical practice. The incidence of life-threatening complications following autologous stem cell transplant proc...
  15. Role of protease activated receptor-2 in tumor advancement of ovarian cancers.

    Annals of Oncology 18(9):1506 (2007) PMID 17761706

    Protease activated receptor-2 (PAR-2) has been implicated in cellular proliferation, invasion and metastasis with angiogenesis in various tumors. This prompted us to study the role of PAR-2 in tumor advancement of ovarian cancers. Forty-eight patients underwent surgery for ovarian cancers. In ov...
  16. Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'.

    Annals of Oncology 18 Suppl 10:x1 (2007) PMID 17761717

    Although single-target agents have been shown to improve patient outcomes in certain tumour types, drug resistance often occurs due to salvage pathways that compensate for the inhibited signalling pathway. Simultaneous inhibition of individual target receptors along multiple pathways has been sh...
  17. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.

    Annals of Oncology 18 Suppl 10:x3 (2007) PMID 17761721

    Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor that targets both angiogenic pathways (i.e., vascular endothelial growth factor receptor and platelet-derived growth factor receptor) and direct pro-oncogenic pathways (e.g., stem-cell factor receptor and FMS-like tyrosine kina...
  18. Occasional FDG PET recognition of in situ breast cancer.

    Annals of Oncology 18(9):1584 (2007) PMID 17761715

  19. Epigenetic modulation of resistance to chemotherapy?

    Annals of Oncology 18(9):1429 (2007) PMID 17761701

  20. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials.

    Annals of Oncology 18(9):1477 (2007) PMID 17515403

    The purpose of this study was to determine the predictive value of breast cancer molecular subclassification regarding the benefit of adjuvant anthracycline-based chemotherapy. Tumor samples from 823 patients included in two randomized trials that compared an anthracycline-based chemotherapy wit...